Patrick Durisch
@dbdurisch.bsky.social
Health Policy - Politique Santé Public Eye (formerly the Berne Declaration)
www.publiceye.ch
www.publiceye.ch
Swiss House rejects EFTA-Mercosur free trade deal www.swissinfo.ch/eng/agribusi...
Swiss House rejects EFTA-Mercosur free trade deal
The Swiss House of Representatives has rejected the free trade deal between EFTA and Mercosur.
www.swissinfo.ch
June 18, 2026 at 10:11 AM
Swiss House rejects EFTA-Mercosur free trade deal www.swissinfo.ch/eng/agribusi...
Reposted by Patrick Durisch
💊 ICIJ found in its yearlong project involving 124 journalists across 37 countries, that pharmaceutical giant Merck's pricing and patent strategies for its cancer drug Keytruda drive up costs and limit patient access to the life-saving treatment.
https://twp.ai/9OXmcX
https://twp.ai/9OXmcX
June 15, 2026 at 12:15 PM
💊 ICIJ found in its yearlong project involving 124 journalists across 37 countries, that pharmaceutical giant Merck's pricing and patent strategies for its cancer drug Keytruda drive up costs and limit patient access to the life-saving treatment.
https://twp.ai/9OXmcX
https://twp.ai/9OXmcX
Reposted by Patrick Durisch
Welcome to EU Corporate Lobby League 2026 where big money = big influence
Today we will reveal:
🏭 Biggest corporate lobby sectors
✂️ Their lobby agenda to cut our protections
💪 What we can do about it
By Corporate Europe Observatory & @lobbycontrol.bsky.social
corporateeurope.org/en/2026/06/e...
Today we will reveal:
🏭 Biggest corporate lobby sectors
✂️ Their lobby agenda to cut our protections
💪 What we can do about it
By Corporate Europe Observatory & @lobbycontrol.bsky.social
corporateeurope.org/en/2026/06/e...
June 11, 2026 at 7:00 AM
Welcome to EU Corporate Lobby League 2026 where big money = big influence
Today we will reveal:
🏭 Biggest corporate lobby sectors
✂️ Their lobby agenda to cut our protections
💪 What we can do about it
By Corporate Europe Observatory & @lobbycontrol.bsky.social
corporateeurope.org/en/2026/06/e...
Today we will reveal:
🏭 Biggest corporate lobby sectors
✂️ Their lobby agenda to cut our protections
💪 What we can do about it
By Corporate Europe Observatory & @lobbycontrol.bsky.social
corporateeurope.org/en/2026/06/e...
Reposted by Patrick Durisch
Wir lehnen die revidierte #KVV Vorlage zu Medikamentenpreisen in der Schweiz ab. Die Einsparungen werden gering bleiben, solange nichts gegen die Machtasymmetrie zwischen #Pharma & BAG unternommen wird. Es braucht eine gründlichere Reform und mehr Transparenz! www.publiceye.ch/de/news/deta...
Überarbeitung des Systems zur Medikamenten­preisfestsetzung: ...
Mit Massnahmen zur Dämpfung der Gesundheitskosten hat das Parlament Geheimrabatte für Medikamente gesetzlich verankert. Nun werden diese und weitere Gesetzesänderungen auf Verordnungsebene k...
www.publiceye.ch
June 4, 2026 at 8:49 AM
Wir lehnen die revidierte #KVV Vorlage zu Medikamentenpreisen in der Schweiz ab. Die Einsparungen werden gering bleiben, solange nichts gegen die Machtasymmetrie zwischen #Pharma & BAG unternommen wird. Es braucht eine gründlichere Reform und mehr Transparenz! www.publiceye.ch/de/news/deta...
@fr.publiceye.ch rejette le projet de révision #OAMal sur le prix des médicaments en 🇨🇭. Les économies resteront modestes tant qu'on n'agira pas sur l'asymétrie de pouvoir entre #pharma et @bag.admin.ch. Il faut une réforme plus drastique & davantage de transparence ! www.publiceye.ch/fr/news/deta...
Révision du système de fixation du prix des médicaments : des éco...
Le Parlement avait décidé de légaliser les rabais secrets sur les médicaments dans le cadre de la modification de la loi sur l’assurance-maladie (LAMal) afin de freiner la hausse des coûts d...
www.publiceye.ch
June 3, 2026 at 2:26 PM
@fr.publiceye.ch rejette le projet de révision #OAMal sur le prix des médicaments en 🇨🇭. Les économies resteront modestes tant qu'on n'agira pas sur l'asymétrie de pouvoir entre #pharma et @bag.admin.ch. Il faut une réforme plus drastique & davantage de transparence ! www.publiceye.ch/fr/news/deta...
Reposted by Patrick Durisch
It was a pleasure to speak with Aisha Nyandoro for @forbes.com on the occasion of the U.S release of Pharma Monopoly. www.forbes.com/sites/aishan...
A Former IP Attorney On Why Drug Pricing Is Really About Power
Pharmaceutical monopolies, patent law, and global health access shaping drug pricing, power, and inequities in the U.S. and worldwide.
www.forbes.com
May 28, 2026 at 7:48 PM
It was a pleasure to speak with Aisha Nyandoro for @forbes.com on the occasion of the U.S release of Pharma Monopoly. www.forbes.com/sites/aishan...
Reposted by Patrick Durisch
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain.
www.statnews.com/2026/05/26/h...
www.statnews.com/2026/05/26/h...
The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
www.statnews.com
May 27, 2026 at 3:33 PM
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain.
www.statnews.com/2026/05/26/h...
www.statnews.com/2026/05/26/h...
Reposted by Patrick Durisch
Happy publication day, Tahir!
Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY, @tahiramin.bsky.social and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.
Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY, @tahiramin.bsky.social and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.
May 26, 2026 at 2:02 PM
Happy publication day, Tahir!
Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY, @tahiramin.bsky.social and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.
Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY, @tahiramin.bsky.social and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.
Reposted by Patrick Durisch
After millions of German and EU subsidies «to create/preserve domestic technological capacity and jobs» BionTech still decides unilaterally to close down factories because it suit their business interests.
When will policy makers step up and implement industrial policy in the public interest?
When will policy makers step up and implement industrial policy in the public interest?
May 8, 2026 at 6:55 AM
After millions of German and EU subsidies «to create/preserve domestic technological capacity and jobs» BionTech still decides unilaterally to close down factories because it suit their business interests.
When will policy makers step up and implement industrial policy in the public interest?
When will policy makers step up and implement industrial policy in the public interest?
Reposted by Patrick Durisch
Wer zahlt am meisten Steuern in der Schweiz? Normalerweise: Roche, Novartis oder Nestlé. Neu zahlt ein US-Pharmakonzern mehr als alle anderen. Deutlich mehr. Die Recherche von @tikollbrunner.bsky.social und mir mit Unterstützung des @icij.org heute auf @republik.ch www.republik.ch/2026/04/17/g...
Geldregen mit Trumps Segen
Warum ein US-Konzern in der Schweiz mehr Steuern bezahlt als Nestlé und Novartis.
www.republik.ch
April 17, 2026 at 9:29 AM
Wer zahlt am meisten Steuern in der Schweiz? Normalerweise: Roche, Novartis oder Nestlé. Neu zahlt ein US-Pharmakonzern mehr als alle anderen. Deutlich mehr. Die Recherche von @tikollbrunner.bsky.social und mir mit Unterstützung des @icij.org heute auf @republik.ch www.republik.ch/2026/04/17/g...
Reposted by Patrick Durisch
Switzerland🇨🇭, MSDs💊 favourite (tax💸) holiday destination 🏝️ @icij.org @phalbrecht.bsky.social @republik.ch #CancerCalculus
Der US-Pharmakonzern MSD erzielt enorme Gewinne. Das freut den Schweizer Fiskus – der Steuern in Milliardenhöhe einstreicht. Ein Geldregen mit Trumps Segen. Jetzt lesen oder anhören - Link im ersten Kommentar.
April 17, 2026 at 10:27 AM
Switzerland🇨🇭, MSDs💊 favourite (tax💸) holiday destination 🏝️ @icij.org @phalbrecht.bsky.social @republik.ch #CancerCalculus
Reposted by Patrick Durisch
Public Citizen’s Peter Maybarduk told ICIJ that pharma created a system of rules to protect drugmakers and ensure wealthy governments protect them “There is a whole architecture underpinning Keytruda and every patented drug where the US government and Europe go to bat for the industry and its rules”
The yearlong investigation by 100+ journalists also sheds new light on the strategies that have allowed Merck to widen Keytruda’s use — even in cases where the benefits are limited and lower dosages may be just as effective. www.icij.org/investigatio...
How Merck turned its wonder drug into a blockbuster — and priced out cancer patients worldwide - ICIJ
The pharmaceutical giant has built a fortress of patents, traded in secrecy and relentlessly lobbied to guard its revenue kingpin Keytruda.
www.icij.org
April 15, 2026 at 1:45 AM
Public Citizen’s Peter Maybarduk told ICIJ that pharma created a system of rules to protect drugmakers and ensure wealthy governments protect them “There is a whole architecture underpinning Keytruda and every patented drug where the US government and Europe go to bat for the industry and its rules”
Thank you @tahiramin.bsky.social @imakglobal.bsky.social for supporting @fr.publiceye.ch in our patent analysis of cancer drug #Keytruda, in conjunction with @icij.org, unveiling MSD's gaming of the patent systems to maintain overinflated prices & delay competition www.publiceye.ch/en/topics/ph...
April 15, 2026 at 9:41 AM
Thank you @tahiramin.bsky.social @imakglobal.bsky.social for supporting @fr.publiceye.ch in our patent analysis of cancer drug #Keytruda, in conjunction with @icij.org, unveiling MSD's gaming of the patent systems to maintain overinflated prices & delay competition www.publiceye.ch/en/topics/ph...
Reposted by Patrick Durisch
#CancerCalculus: An ICIJ-led collaboration with 47 media partners in 37 countries reveals how Merck & Co. keeps the price of its lifesaving cancer drug Keytruda sky-high, locking out patients and squeezing health care systems worldwide. www.icij.org/investigatio...
April 13, 2026 at 4:12 PM
#CancerCalculus: An ICIJ-led collaboration with 47 media partners in 37 countries reveals how Merck & Co. keeps the price of its lifesaving cancer drug Keytruda sky-high, locking out patients and squeezing health care systems worldwide. www.icij.org/investigatio...
Reposted by Patrick Durisch
Prix record, brevets en cascade et coûts de recherche contestés: une enquête de l’ONG Public Eye et du Consortium international des journalistes d’investigation révèle comment l’anticancéreux phare de MSD s’est imposé comme...
Keytruda: les dessous d’un médicament star aux marges hors norme
l.letemps.ch
April 13, 2026 at 6:58 AM
Prix record, brevets en cascade et coûts de recherche contestés: une enquête de l’ONG Public Eye et du Consortium international des journalistes d’investigation révèle comment l’anticancéreux phare de MSD s’est imposé comme...
Reposted by Patrick Durisch
Our first—and hopefully not our last—collaboration with our colleagues at the @icij.org ✊🏼 @republik.ch #CancerCalculus
Zusammen mit @icij.org haben @phalbrecht.bsky.social und ich für die @republik.ch recherchiert, warum die Krebstherapie Keytruda die Welt – und die Schweiz – so viel kostet wie kein anderes Medikament. Und wieso sich daran nichts ändert. #CancerCalculus
www.republik.ch/2026/04/13/d...
www.republik.ch/2026/04/13/d...
Das Medikament, das alles sprengt
Kein Arzneimittel kostet die Welt so viel wie die Krebstherapie Keytruda. Wer profitiert?
www.republik.ch
April 13, 2026 at 2:34 PM
Our first—and hopefully not our last—collaboration with our colleagues at the @icij.org ✊🏼 @republik.ch #CancerCalculus
Reposted by Patrick Durisch
Zusammen mit @icij.org haben @phalbrecht.bsky.social und ich für die @republik.ch recherchiert, warum die Krebstherapie Keytruda die Welt – und die Schweiz – so viel kostet wie kein anderes Medikament. Und wieso sich daran nichts ändert. #CancerCalculus
www.republik.ch/2026/04/13/d...
www.republik.ch/2026/04/13/d...
Das Medikament, das alles sprengt
Kein Arzneimittel kostet die Welt so viel wie die Krebstherapie Keytruda. Wer profitiert?
www.republik.ch
April 13, 2026 at 9:24 AM
Zusammen mit @icij.org haben @phalbrecht.bsky.social und ich für die @republik.ch recherchiert, warum die Krebstherapie Keytruda die Welt – und die Schweiz – so viel kostet wie kein anderes Medikament. Und wieso sich daran nichts ändert. #CancerCalculus
www.republik.ch/2026/04/13/d...
www.republik.ch/2026/04/13/d...
Reposted by Patrick Durisch
💊 En Suisse, le médicament anticancéreux #Keytruda a permis au géant pharmaceutique MSD de réaliser un chiffre d'affaires de 31,7 milliards de dollars en 2025. Notre enquête conjointe avec @icij.org montre comment MSD fait du « patent evergreening »➡️ www.publiceye.ch/fr/keytruda
Une dose de cet anticancéreux coûte plus cher qu’une once d’or
Le Keytruda du géant étatsunien Merck Sharp & Dohme (MSD) représente un réel espoir pour les malades du cancer et les oncologues. Il est aussi le cauchemar des assureurs et des budgets de santé publiq...
www.publiceye.ch
April 13, 2026 at 12:13 PM
💊 En Suisse, le médicament anticancéreux #Keytruda a permis au géant pharmaceutique MSD de réaliser un chiffre d'affaires de 31,7 milliards de dollars en 2025. Notre enquête conjointe avec @icij.org montre comment MSD fait du « patent evergreening »➡️ www.publiceye.ch/fr/keytruda
Reposted by Patrick Durisch
Read the Principles for Access to Medicines and Trade: www.citizen.org/news/more-th...
More Than 100 Organizations Urge Countries to Resist Trump’s Trade Attacks, Protect Access to Affordable Medicines - Public Citizen
WASHINGTON, D.C. — Public Citizen, Health GAP, and 99 expert organizations from around the world are calling for an approach…
www.citizen.org
February 19, 2026 at 4:23 PM
Read the Principles for Access to Medicines and Trade: www.citizen.org/news/more-th...
Reposted by Patrick Durisch
The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines.
Experts from around the world offer an alternate vision:
Experts from around the world offer an alternate vision:
February 19, 2026 at 4:23 PM
The Trump administration is using U.S. trade power and extreme tariffs to bully other countries into binding agreements that undermine affordable and readily available access to medicines.
Experts from around the world offer an alternate vision:
Experts from around the world offer an alternate vision:
"Pharmaceutical companies are raising prices elsewhere instead of bringing them down in the US, due to rules introduced by President Donald Trump that force drugmakers to reduce their prices in the US to the lowest level paid in other developed countries." www.bloomberg.com/news/article...
Trump’s Attempt to Make Drugs Cheaper Is Pushing Up Prices in Other Countries
The president’s order is upending health care in Switzerland.
www.bloomberg.com
February 4, 2026 at 3:28 PM
"Pharmaceutical companies are raising prices elsewhere instead of bringing them down in the US, due to rules introduced by President Donald Trump that force drugmakers to reduce their prices in the US to the lowest level paid in other developed countries." www.bloomberg.com/news/article...
Reposted by Patrick Durisch
Trump says he lowered drug prices.
We’ll believe it when we see it.
So we sued for access to the secret deals.
We’ll believe it when we see it.
So we sued for access to the secret deals.
NEW LAWSUIT: We sued the Trump admin for failing to respond to FOIA requests about the admin’s drug-pricing deals with Pfizer & Eli Lilly.
Americans deserve to see these deals, which affect prices that we pay for Rx drugs.
Americans deserve to see these deals, which affect prices that we pay for Rx drugs.
February 3, 2026 at 5:07 PM
Trump says he lowered drug prices.
We’ll believe it when we see it.
So we sued for access to the secret deals.
We’ll believe it when we see it.
So we sued for access to the secret deals.
"Die Basler drohen der 🇨🇭 mit Jobabbau und dem Zurückhalten ihres neuen «revolutionären» Brustkrebsmedikaments." Eine Frechheit von #Roche als sie fast 14 Milliarden Franken Reingewinn im 2025 machten.
Erpressen & jammern, das können sie weiterhin gut🤔 www.tagesanzeiger.ch/roche-droht-...
Erpressen & jammern, das können sie weiterhin gut🤔 www.tagesanzeiger.ch/roche-droht-...
Wegen Trump: Neues Brustkrebsmedikament könnte Schweizer Kassen sprengen
Giredestrant soll zum neuen Standard bei Brustkrebs werden. Wegen des US-Deals muss Roche den Preis der Therapie vielleicht anheben. Und zwar so stark, dass ihn Krankenkassen nicht mehr erstatten könnten.
www.tagesanzeiger.ch
January 29, 2026 at 4:58 PM
"Die Basler drohen der 🇨🇭 mit Jobabbau und dem Zurückhalten ihres neuen «revolutionären» Brustkrebsmedikaments." Eine Frechheit von #Roche als sie fast 14 Milliarden Franken Reingewinn im 2025 machten.
Erpressen & jammern, das können sie weiterhin gut🤔 www.tagesanzeiger.ch/roche-droht-...
Erpressen & jammern, das können sie weiterhin gut🤔 www.tagesanzeiger.ch/roche-droht-...
Alors que le lobby pharma ne cesse de se lamenter sur les vélléités 🇺🇸 (inoffensives pour l'instant) de baisser le prix des médicaments, le géant bâlois #Roche annonce des bénéfices nets de CHF 13,8 milliards en 2025 ! Ça va, il y a encore de la marge (bénéficiaire) 🤔 www.publiceye.ch/fr/regard/de...
Deals des pharmas suisses aux États-Unis: une farce au goût amer
Peu avant Noël, les géants bâlois Roche et Novartis ont conclu un « deal » très attendu avec la Maison blanche sur le prix des médicaments aux États-Unis. Contrairement à ce qu’on pourrait croire, le ...
www.publiceye.ch
January 29, 2026 at 8:57 AM
Alors que le lobby pharma ne cesse de se lamenter sur les vélléités 🇺🇸 (inoffensives pour l'instant) de baisser le prix des médicaments, le géant bâlois #Roche annonce des bénéfices nets de CHF 13,8 milliards en 2025 ! Ça va, il y a encore de la marge (bénéficiaire) 🤔 www.publiceye.ch/fr/regard/de...
Reposted by Patrick Durisch
Plainte en diffamation de Kolmar: les autrices et l’auteur d’un rapport de Public Eye et TRIAL ont été acquitté·e·s des charges de « diffamation voire calomnie ». La Cour a balayé l’appel et confirmé la solidité de notre enquête. Un signal fort pour la liberté d’informer ! 👉 peye.link/plainte-kolmar
Plainte en diffamation de Kolmar: un second acquittement importan...
Dans le cadre d’une procédure en appel, la justice bernoise a acquitté aujourd’hui des charges de «diffamation voire calomnie» les autrices et l’auteur d’un rapport de Public Eye et TRIAL In...
www.publiceye.ch
January 28, 2026 at 6:23 PM
Plainte en diffamation de Kolmar: les autrices et l’auteur d’un rapport de Public Eye et TRIAL ont été acquitté·e·s des charges de « diffamation voire calomnie ». La Cour a balayé l’appel et confirmé la solidité de notre enquête. Un signal fort pour la liberté d’informer ! 👉 peye.link/plainte-kolmar